Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - transdermal nitroglycerin is indicated for the prevention of angina pectoris due to coronary artery disease. the onset of action of transdermal nitroglycerin is not sufficiently rapid for this product to be useful in aborting an acute attack. allergic reactions to organic nitrates are extremely rare, but they do occur. nitroglycerin is contraindicated in patients who are allergic to it. allergy to the adhesives used in nitroglycerin patches has also been reported, and it similarly constitutes a contraindication to the use of this product. do not use nitroglycerin transdermal systems in patients who are taking phosphodiesterase inhibitors (such as sildenafil, tadalafil, or vardenafil) for erectile dysfunction or pulmonary arterial hypertension. concomitant use can cause severe drops in blood pressure. do not use nitroglycerin transdermal systems in patients who are taking the soluble guanylate cyclase stimulator riociguat. concomitant use can cause hypotension.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin ointment is indicated for the prevention of angina pectoris due to coronary artery disease. the onset of action of transdermal nitroglycerin is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. allergic reactions to organic nitrates are extremely rare, but they do occur. nitroglycerin is contraindicated in patients who are allergic to it.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

parke-davis div of pfizer inc - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 0.3 mg - nitrostat is indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. do not use nitrostat in patients who are taking pde-5 inhibitors, such as avanafil, sildenafil, tadalafil, vardenafil hydrochloride. concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see drug interactions (7.1)]. do not use nitrostat in patients who are taking the soluble guanylate cyclase stimulators, such as riociguat. concomitant use can cause hypotension. nitrostat is contraindicated in patients with severe anemia (large doses of nitroglycerin may cause oxidation of hemoglobin to methemoglobin and could exacerbate anemia). nitrostat may precipitate or aggravate increased intracranial pressure and thus should not be used in patients with possible increased intracranial pressure (e.g., cerebral hemorrhage or traumatic brain injury). nitrostat is contraindicated in patients who are allergic to nitroglycerin, other nitrates or nitrites or any excipient. nitrostat is contraindicated in patients with acute circulatory failure or shock. risk summary limited published data on the use of nitroglycerin are insufficient to determine a drug associated risk of major birth defects or miscarriage. in animal reproduction studies, there were no adverse developmental effects when nitroglycerin was administered intravenously to rabbits or intraperitoneally to rats during organogenesis at doses greater than 64-times the human dose [see data] . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively. data animal data no embryotoxic or postnatal development effects were observed with transdermal application in pregnant rabbits and rats at doses up to 80 and 240 mg/kg/day, respectively, at intraperitoneal doses in pregnant rats up to 20 mg/kg/day from gestation day 7–17, and at intravenous doses in pregnant rabbits up to 4 mg/kg/day from gestation day 6–18. risk summary sublingual nitroglycerin has not been studied in lactating women. it is not known if nitroglycerin is present in human milk or if nitroglycerin has effects on milk production. the safety and effectiveness of nitroglycerin in pediatric patients have not been established. clinical studies of nitrostat did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

remedyrepack inc. - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 0.4 mg - nitrostat is indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. do not use nitrostat in patients who are taking pde-5 inhibitors, such as avanafil, sildenafil, tadalafil, vardenafil hydrochloride. concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see drug interactions (7.1)]. do not use nitrostat in patients who are taking the soluble guanylate cyclase stimulators, such as riociguat. concomitant use can cause hypotension. nitrostat is contraindicated in patients with severe anemia (large doses of nitroglycerin may cause oxidation of hemoglobin to methemoglobin and could exacerbate anemia). nitrostat may precipitate or aggravate increased intracranial pressure and thus should not be used in patients with possible increased intracranial pressure (e.g., cerebral hemorrhage or traumatic brain injury). nitrostat is contraindicated in patients who are allergic to nitroglycerin, other nitrat

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

jacksonville pharmaceuticals, inc. - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 400 ug - nitroglycerin lingual spray is indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. do not use nitroglycerin lingual spray in patients who are taking pde-5-inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil. concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see drug interactions (7.1) ]. do not use nitroglycerin lingual spray in patients who are taking soluble guanylate cyclase (sgc) stimulators, such as riociguat. concomitant use can cause hypotension. nitroglycerin lingual spray is contraindicated in patients with severe anemia (large doses of nitroglycerin may cause oxidation of hemoglobin to methemoglobin and could exacerbate anemia). nitroglycerin lingual spray  may precipitate or aggravate increased intracranial pressure and thus should not be used in patients with possible increased intracranial pressure (e. g. cerebral hemorrhage or traumatic brain injury). nitroglycerin lingual spray is c

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

espero pharmaceuticals, inc. - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 400 ug - nitrolingual pumpspray is indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. do not use nitrolingual pumpspray in patients who are taking pde-5-inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil. concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see drug interactions (7.1) ]. do not use nitrolingual pumpspray in patients who are taking soluble guanylate cyclase (sgc) stimulators, such as riociguat. concomitant use can cause hypotension. nitrolingual pumpspray is contraindicated in patients with severe anemia (large doses of nitroglycerin may cause oxidation of hemoglobin to methemoglobin and could exacerbate anemia). nitrolingual pumpspray  may precipitate or aggravate increased intracranial pressure and thus should not be used in patients with possible increased intracranial pressure (e. g. cerebral hemorrhage or traumatic brain injury). nitrolingual pumpspray is contraindicated in patients who are allergic t

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

espero pharmaceuticals, inc. - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 400 ug - gonitro is indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. do not use gonitro in patients who are taking pde-5-inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil. concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see drug interactions (7.1) ]. do not use gonitro in patients who are taking soluble guanylate cyclase (sgc) stimulators, such as riociguat. concomitant use can cause hypotension. gonitro is contraindicated in patients with severe anemia (large doses of nitroglycerin may cause oxidation of hemoglobin to methemoglobin and could exacerbate anemia). gonitro may precipitate or aggravate increased intracranial pressure and thus should not be used in patients with possible increased intracranial pressure (e. g. cerebral hemorrhage or traumatic brain injury). gonitro is contraindicated in patients who are allergic to nitroglycerin, other nitrates or nitrites or any excipient. gonitro is contraindicated in

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

prostrakan, inc. - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 4 mg in 1 g - rectiv™ (nitroglycerin) ointment 0.4% is indicated for the treatment of moderate to severe pain associated with chronic anal fissure. administration of rectiv is contraindicated in patients who are using a selective inhibitor of cyclic guanosine monophosphate (cgmp)-specific phosphodiesterase type 5 (pde5), such as sildenafil, vardenafil, and tadalafil, as these are shown to potentiate the hypotensive effects of organic nitrates [see 7.1 drug interactions]. rectiv is contraindicated in patients with severe anemia. rectiv is contraindicated in patients with increased intracranial pressure. rectiv is contraindicated in patients who have shown hypersensitivity to it or to other nitrates or nitrites. skin reactions consistent with hypersensitivity have been observed with organic nitrates. pregnancy category c animal reproduction and teratogenicity studies have not been conducted with rectiv. nitroglycerin was not teratogenic when administered by topical or dietary route. there are no adequate and w

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

allergan, inc. - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 4 mg in 1 g - rectiv® (nitroglycerin) ointment 0.4% is indicated for the treatment of moderate to severe pain associated with chronic anal fissure. administration of rectiv is contraindicated in patients who are using a selective inhibitor of cyclic guanosine monophosphate (cgmp)-specific phosphodiesterase type 5 (pde5), such as sildenafil, vardenafil, and tadalafil, as these are shown to potentiate the hypotensive effects of organic nitrates [see 7.1 drug interactions]. rectiv is contraindicated in patients with severe anemia. rectiv is contraindicated in patients with increased intracranial pressure. rectiv is contraindicated in patients who have shown hypersensitivity to it or to other nitrates or nitrites. skin reactions consistent with hypersensitivity have been observed with organic nitrates. pregnancy category c animal reproduction and teratogenicity studies have not been conducted with rectiv. nitroglycerin was not teratogenic when administered by topical or dietary route. there are no adequate and well-controlled

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

antigen laboratories, inc. - glycerin (unii: pdc6a3c0ox) (glycerin - unii:pdc6a3c0ox) - glycerin 0.525 ml in 1 ml - allergenic extract is used for diagnostic testing and for the treatment (immunotherapy) of patients whose histories indicate that upon natural exposure to the allergen, they experience allergic symptoms. confirmation is determined by skin testing. diagnostic use of allergenic extracts usually begins with direct skin testing. this product is not intended for treatment of patients who do not manifest immediate hypersensitivity reactions to the allergenic extract following skin testing. do not administer in the presence of diseases characterized by bleeding diathesis. individuals with autoimmune disease may be at risk of exacerbating symptoms of the underlying disease, possibly due to routine immunization. patients who have experienced a recent myocardial infarction may not be tolerant of immunotherapy. children with nephrotic syndrome probably should not receive injections due to immunization causing exacerbation of nephrotic disease.